Yongin Mayor Baek Goon-ki Congratulates Domestic First Approval of Pet Cognitive Dysfunction Treatment Drug

[Suwon Ilbo=Reporter Park No-hun] "I am delighted that a pet cognitive dysfunction treatment drug developed by a company in our jurisdiction has received Korea's first new drug approval, raising our status as an enterprise city."

Baek Goon-ki, Mayor of Yongin, made the remarks on the 15th during a meeting with Kwak Byung-joo, CEO of GNTi Pharma, a new drug development venture company located in Hagal-dong, Giheung-gu, at the mayor's office at City Hall.

This follows GNTi Pharma's pet cognitive dysfunction syndrome treatment drug 'Jedacure' receiving Korea's first animal pharmaceutical product approval from the Animal and Plant Quarantine Agency on the 2nd.

Jedacure is the product name for crisdesalarizine, a new veterinary drug developed by the company with support from the Ministry of Science and ICT and the Ministry of Health and Welfare.

At the meeting, CEO Kwak stated, "Since Jedacure has proven efficacy and safety for dogs suffering from cognitive dysfunction, it is expected to make a significant contribution to the health maintenance of aging dogs."

He added, "If distribution channels open in domestic and international markets in the future, enormous production facilities will be needed, and I hope the city will cooperate positively."

Mayor Baek said, "I am grateful that GNTi Pharma has raised the city's status as a representative Korean company, and I sincerely congratulate them on the new drug approval. We will support management activities through various administrative support measures."

Meanwhile, GNTi Pharma has completed U.S. and PCT (Patent Cooperation Treaty) international patent applications for Jedacure and is currently in discussions with global veterinary pharmaceutical companies regarding distribution.

The company added that this new drug approval is an achievement made in the process of developing Korea's first Alzheimer's treatment drug for humans with government funding support since 2003. The company is expected to continue this research and bring hope to dementia patients and their families.